Charged Alpha Stock Encyclopedia

NIKE, Inc. (NKE) Q1 FY2027 — The saved $32.78 after-hours reference was 6.74% below the $35.15 regular-session close. The next-session closing reaction remains pending. THE CALL: SELL (3/5, MODERATE) — base-case value ~$25.00 vs ~$32.78 at the saved October 1, 2026 after-hours reference. KEY METRICS: - Q1 revenue $11.213B; gross margin 42.8%; diluted EPS $0.48 - FY2027 adjusted EPS guide $1.15–$1....

Accenture plc (ACN) Q4 FY2026 — The valuation uses a saved $214.50 October 1 premarket observation. The September 30 completed close was $183.37; no October 1 closing reaction is claimed. THE CALL: HOLD (3/5, MODERATE) — base-case value ~$250.00 vs ~$214.50 at the saved October 1, 2026 premarket reference. KEY METRICS: - Q4 revenue $18.679B; diluted EPS $3.29, up 46% GAAP or 9% against adjusted pr...

Jabil Inc. (JBL) Q4 FY2026 — The valuation reference is the September 29 pre-print close of $318.84; this is not a post-release trading price. THE CALL: HOLD (3/5, MODERATE) — base-case value ~$300.00 vs ~$318.84 at the September 29, 2026 pre-print close. KEY METRICS: - Q4 revenue $10.616B, up 28.6%; core EPS $4.40, up 33.7%; GAAP EPS $3.76 - FY2026 OCF $2.002B; operating asset cash use $7.846B of...

Conagra Brands, Inc. (CAG) Q1 FY2027 — Reference price $14.12 is the September 29 quote before the release; a post-print reaction is not established in the saved data. Adjusted EPS rose 5.1%, while adjusted operating profit fell 4.1%. Joint-venture income and expense benefits supported the headline; cash coverage decides whether the recovery can fund the dividend and debt. THE CALL: HOLD (3/5, MOD...

Cal-Maine Foods, Inc. (CALM) Q1 FY2027 — The $68.55 reference is the September 29 pre-release close; no post-release price reaction is asserted. Cal-Maine's specialty and prepared-food businesses reached 54.1% of external sales, but all three reportable segments earned less. Conventional egg prices fell sharply, free cash flow turned negative, and the dividend remains behind a cumulative-loss reco...

Uranium Energy Corp. (UEC) FY2026 — Saved intraday reference $9.045; no completed current-day earnings reaction asserted. Uranium Energy reported $753M of liquid assets, but unrestricted cash was $495M and shareholders supplied $530M of net financing. Mine costs improved. We trace what the cash can fund, what conversion still needs, and the assumptions required to justify the valuation. THE CALL:...

CarMax, Inc. (KMX) Q2 FY2027 — Saved intraday reference $59.10 at 15:36 UTC; the current earnings-day close is not yet known. CarMax sold more cars and spread overhead across more transactions. Lower provisions, a loan-sale gain and investment income also helped profits. We separate repeatable operating progress from those contributions before valuing the recovery. THE CALL: HOLD (3/5, MODERATE) —...

IDT Corporation (IDT) Q4 FY2026 — Saved regular-session reference $69.61; exact release clock unverified, so no earnings reaction is asserted. Record operating results meet a cash-conversion test. IDT guides to higher FY2027 gross profit and adjusted EBITDA, but settlement funding absorbed cash as its growth businesses expanded. We trace the earnings, customer deposits and subsidiary ownership bef...

Vail Resorts (MTN) Q4 FY2026 — Saved regular-session reference $138.07; no post-release reaction asserted. Vail generated $248M of free cash flow while paying $317M in dividends and $45M in buybacks. Advance pass dollars are down 6%. Can the guided recovery close the shareholder cash gap? THE CALL: HOLD (3/5, MODERATE) — base-case value ~$125.00 vs ~$138.07 at the saved regular-session reference....

Rezolute, Inc. (RZLT) Q4 FY2026 — RZLT closed at $3.94 on September 24, down 1.5% for the reporting day. The midday release means this is not an isolated earnings reaction. Seven of the initial eight upLIFT tumor-study participants met the response threshold, but the trial remains incomplete. The congenital sunRIZE study failed its primary and key secondary endpoints, and FDA review has no stated...

Uxin Limited (UXIN) Q2 2026 — UXIN closed September 24 at $1.30, up 19.3% from $1.09, on 16.08 million ADSs traded; the regular-session range was $1.1707 to $1.41. Uxin nearly doubled retail vehicle volume, but inventory-price pressure drove gross margin to negative 0.7%. The next print must prove that the reset restored vehicle economics while financing and dilution remain central to common-equit...

Costco Wholesale Corporation (COST) Q4 FY2026 — An early after-hours trade was $897.02 at 16:29 ET on September 24, about 0.06% above the $896.48 regular close; this was not a completed post-print session. Costco delivered 12.4% normalized EPS growth after removing a $0.15 non-recurring tariff-refund benefit. The business remains exceptional, but the early price requires roughly 18.5% annual owner...

TD SYNNEX Corporation (SNX) Q3 FY2026 — A thin pre-market trade was $256.60 at 08:31 ET on September 24, about 10.9% below the $287.89 prior close; the nearby bid/ask spread was wide. TD SYNNEX reported record operating profit, but quarterly free cash flow was negative $975.6 million. Inventory and receivables are consuming capital, making cash conversion the test of the stronger earnings engine....

General Mills (GIS) Q1 FY2027 — Saved September 23 intraday quote $35.74, +0.82% from prior close; the session was not complete. Flat organic sales hide a $99M segment-profit decline in Retail and Pet. International and Foodservice offset only $18.3M. Can stabilization become profitable growth? THE CALL: HOLD (3/5, MODERATE) — base-case value ~$37.00 vs ~$35.74 today. KEY METRICS: - Revenue $4,389...

Paychex, Inc. (PAYX) Q1 FY2027 — The saved September 23 intraday quote was $105.81, down 7.61% from the prior close; the session had not yet closed. Paychex paid more in dividends than quarterly free cash flow, even as margins improved. Three cash-flow lines explain most of the decline, and trailing cash still covers the payout. The question is what recovers after integration costs and debt servic...

Manchester United (MANU) Q4 FY2026 — Reference $20.51 is the September 22 close, before this print; post-print reaction unavailable. Champions League participation lifts Manchester United’s revenue outlook, but guided EBITDA is roughly flat. Player investment, higher net debt and stadium funding keep the shareholder cash question open. THE CALL: SELL (3/5, MODERATE) — base-case value ~$13.50 vs ~$...

KB Home (KBH) Q3 FY2026 — Reference price $48.59 from the saved September 22 quote; a post-print reaction is not verified. Backlog grew, but demand per community weakened. KB Home’s sequential margin recovery meets rising net debt and a book value dominated by inventory. THE CALL: HOLD (3/5, MODERATE) — base-case value ~$50.00 vs ~$48.59 today. KEY METRICS: - Revenue $1,297.101M, down 19.96% YoY -...

AutoZone, Inc. (AZO) Q4 FY2026 — The reference is the September 21 close of $2,803.25, before this earnings release; no verified post-print move is asserted. AutoZone’s gross margin rebounded, but tariff refunds and the comparative LIFO benefit explain more than the entire improvement. Commercial growth remains strong while inventory and investment absorb cash. THE CALL: HOLD (3/5, MODERATE) — bas...

THOR Industries (THO) Q4 FY2026 — The valuation uses the September 21 pre-print close of $69.94; no post-print reaction is asserted. THOR promises over $100M of annual earnings improvement once its initiatives are fully implemented. Meanwhile, FY2026 free cash flow fell to $168.8M and dividends plus buybacks ran ahead of it. Can the savings become cash without a retail rebound? THE CALL: HOLD (3/5...

AnaptysBio, Inc. (ANAB) Q2 2026 — September 21 close $54.99, down 0.39%; the release-session label is unverified, so this is not necessarily a clean post-print reaction baseline. Anaptys reported $5.11 of Q2 diluted EPS, but a $181.491M tax benefit drove the profit. The real value remains the post-Sagard Jemperli royalty stream, under an agreement now in unresolved litigation. THE CALL: HOLD (3/5,...

Abivax S.A. (ABVX) Q2 2026 — September 21 saved close $103.45, down 1.51% from $105.04. SEC acceptance metadata and the issuer release dateline conflict, so no reaction baseline is claimed. Abivax now has funding into Q4 2029 and a planned obefazimod NDA, but nearly $8.6B of diluted value above capital leaves little room for execution mistakes. THE CALL: HOLD (3/5, MEDIUM) — base-case value ~$110....

Innate Pharma S.A. (IPHA) H1 2026 — September 17 intraday quote $1.855 at 11:50 a.m. EDT, down 7.71% from the $2.01 previous close. Not the final session close. Innate Pharma closed the Sobi partnership and an equity financing, extending the expected runway. The cash has claims, the shares have new owners, and clinical evidence still determines the value. THE CALL: HOLD (2/5, LOW) — base-case valu...

Immersion Corporation (IMMR) Q1 FY2027 — FMP September 16 regular close $7.12; financial anchor July 31 and latest common count September 8. Post-release dated observation, not a live quote. Immersion returned to parent-attributable profit, but investment gains did much of the work. We separate recurring haptic economics, BNED minority ownership and claims against the parent cash balance. THE CALL...

Uranium Royalty Corp. (UROY) Q1 FY2027 — September 16 regular-session close: $4.39. Current economic shares include common and exchangeable claims. Uranium Royalty reported sharply higher earnings while monetizing its remaining physical stockpile. Sweetwater changed the share count, debt and cash priorities, and a $40M bridge must be repaid by January 31, 2027. THE CALL: SELL (2/5, LOW) — base-cas...

Aeluma, Inc. (ALMU) Q4 FY2026 — The saved preliminary after-hours trade was $11.10 at 19:58:09 EDT on September 16, down 17.35% from the $13.43 regular-session close. Aeluma has cash for development, but its conditional CHIPS proposal involves equity securities equal in value to the award. Commercial demand must still justify the higher spending and ownership claims. THE CALL: SELL (2/5, LOW) — ba...